超越美国食品药品监督管理局的患者报告结果指南：将有意义的患者报告结果纳入监管试验和美国药品标签的步骤。 - Suppr

Suppr

超能文献

Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.

作者信息

Basch Ethan

出版信息

Value Health. 2012 May;15(3):401-3. doi: 10.1016/j.jval.2012.03.1385.

DOI:10.1016/j.jval.2012.03.1385

PMID:22583448

Abstract

摘要

相似文献

Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.

Value Health. 2012 May;15(3):401-3. doi: 10.1016/j.jval.2012.03.1385.

A review of patient-reported outcome labels in the United States: 2006 to 2010.

Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032. Epub 2012 Feb 2.

US FDA patient-reported outcome guidance: great expectations and unintended consequences.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):441-6. doi: 10.1586/14737167.2013.814957.

Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.

Control Clin Trials. 2004 Dec;25(6):535-52. doi: 10.1016/j.cct.2004.09.003.

How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.

Health Qual Life Outcomes. 2006 Sep 27;4:69. doi: 10.1186/1477-7525-4-69.

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.

Eur J Cancer. 2009 Feb;45(3):347-53. doi: 10.1016/j.ejca.2008.09.032. Epub 2008 Nov 14.

Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.

Value Health. 2012 May;15(3):443-8. doi: 10.1016/j.jval.2012.01.010.

Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.

Value Health. 2003 Sep-Oct;6(5):522-31. doi: 10.1046/j.1524-4733.2003.65309.x.

Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.

Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):407-20. doi: 10.1586/erp.10.45.

Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.

Cancer. 2014 Mar 1;120(5):761-7. doi: 10.1002/cncr.28470. Epub 2013 Dec 5.

引用本文的文献

Patient perspectives in adverse event reporting after vaginal apical prolapse surgery.

Am J Obstet Gynecol. 2024 Aug;231(2):268.e1-268.e16. doi: 10.1016/j.ajog.2024.04.043. Epub 2024 May 6.

Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review.

Patient. 2024 Jul;17(4):335-347. doi: 10.1007/s40271-024-00689-4. Epub 2024 Apr 8.

A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors.

Cancers (Basel). 2022 Mar 25;14(7):1670. doi: 10.3390/cancers14071670.

Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.

Cancer Med. 2020 Oct;9(20):7363-7374. doi: 10.1002/cam4.3335. Epub 2020 Aug 26.

How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.

J Neurol. 2019 Dec;266(12):3038-3046. doi: 10.1007/s00415-019-09527-2. Epub 2019 Sep 9.

INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.

J Neurol. 2018 Feb;265(2):402-409. doi: 10.1007/s00415-017-8698-2. Epub 2017 Dec 21.

Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.

J Cancer Res Clin Oncol. 2017 Apr;143(4):735-743. doi: 10.1007/s00432-016-2335-9. Epub 2017 Jan 16.

AbobotulinumtoxinA (Dysport) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy.

J Child Neurol. 2017 Apr;32(5):482-487. doi: 10.1177/0883073816686910. Epub 2017 Jan 9.

Patient-reported outcome measures in older people with hip fracture: a systematic review of quality and acceptability.

Qual Life Res. 2017 Apr;26(4):799-812. doi: 10.1007/s11136-016-1424-1. Epub 2016 Oct 20.

The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.

Support Care Cancer. 2016 Aug;24(8):3669-76. doi: 10.1007/s00520-016-3297-9. Epub 2016 Jun 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验